IgA Nephropathy
| Autor: | Mark Haas, Heather N. Reich, Jennifer C. Rodrigues |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Epidemiology 030232 urology & nephrology Urology urologic and male genital diseases Conservative Treatment Critical Care and Intensive Care Medicine Nephropathy 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Humans Immunologic Factors Medicine Glomerular disease Renal Insufficiency Chronic Hematuria Transplantation Series (stratigraphy) business.industry Glomerulonephritis IGA Mycophenolic Acid medicine.disease Glomerular Diseases: Update for the Clinician Proteinuria Phenotype 030104 developmental biology Nephrology Drug Therapy Combination Rituximab business |
| Zdroj: | Clinical Journal of the American Society of Nephrology. 12:677-686 |
| ISSN: | 1555-905X 1555-9041 |
| DOI: | 10.2215/cjn.07420716 |
| Popis: | IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international collaborative efforts have led to important discoveries that have improved our understanding of some of the key steps involved in the immunopathogenesis of IgAN. Furthermore, establishment of multicenter networks has contributed to rigorous design and execution of clinical trials that have provided important insights regarding immunotherapy in IgAN. In this article, we review emerging developments in clinical and translational IgAN research and describe how these novel findings will influence future strategies to improve the outcome of patients with IgAN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|